BNP Paribas Financial Markets’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-6,061
| Closed | -$55.3K | – | 5736 |
|
|
2025
Q2 | $55.3K | Sell |
6,061
-66,202
| -92% | -$487K | ﹤0.01% | 4224 |
|
|
2025
Q1 | $574K | Sell |
72,263
-5,297
| -7% | -$38.8K | ﹤0.01% | 3110 |
|
|
2024
Q4 | $421K | Buy |
77,560
+6,574
| +9% | +$40.2K | ﹤0.01% | 3402 |
|
|
2024
Q3 | $513K | Buy |
70,986
+24,356
| +52% | +$223K | ﹤0.01% | 2845 |
|
|
2024
Q2 | $506K | Sell |
46,630
-150,459
| -76% | -$1.93M | ﹤0.01% | 2663 |
|
|
2024
Q1 | $3.69M | Sell |
197,089
-139,007
| -41% | -$3.21M | ﹤0.01% | 1655 |
|
|
2023
Q4 | $7.28M | Sell |
336,096
-10,011
| -3% | -$198K | 0.01% | 1205 |
|
|
2023
Q3 | $7.12M | Buy |
346,107
+299,135
| +637% | +$8.64M | 0.01% | 1059 |
|
|
2023
Q2 | $2.21M | Sell |
46,972
-24,704
| -34% | -$1.23M | ﹤0.01% | 1699 |
|
|
2023
Q1 | $3.01M | Sell |
71,676
-32,564
| -31% | -$1.4M | ﹤0.01% | 1553 |
|
|
2022
Q4 | $3.98M | Sell |
104,240
-16,589
| -14% | -$634K | 0.01% | 1427 |
|
|
2022
Q3 | $4.73M | Buy |
120,829
+18,804
| +18% | +$727K | 0.01% | 1392 |
|
|
2022
Q2 | $3.3M | Buy |
102,025
+79,740
| +358% | +$2.67M | 0.01% | 1455 |
|
|
2022
Q1 | $738K | Buy |
22,285
+16,715
| +300% | +$628K | ﹤0.01% | 2521 |
|
|
2021
Q4 | $237K | Buy |
5,570
+725
| +15% | +$30.4K | ﹤0.01% | 3333 |
|
|
2021
Q3 | $215K | Buy |
4,845
+2,886
| +147% | +$132K | ﹤0.01% | 3015 |
|
|
2021
Q2 | $111K | Buy |
1,959
+1,688
| +623% | +$119K | ﹤0.01% | 3008 |
|
|
2021
Q1 | $20.3K | Sell |
271
-1,978
| -88% | -$162K | ﹤0.01% | 3758 |
|
|
2020
Q4 | $195K | Buy |
2,249
+1,218
| +118% | +$89.8K | ﹤0.01% | 2894 |
|
|
2020
Q3 | $63K | Sell |
1,031
-102,585
| -99% | -$5.2M | ﹤0.01% | 3358 |
|
|
2020
Q2 | $4.31M | Buy |
103,616
+65,215
| +170% | +$2.37M | 0.01% | 1115 |
|
|
2020
Q1 | $1.1M | Buy |
38,401
+17,564
| +84% | +$1.02M | ﹤0.01% | 1850 |
|
|
2019
Q4 | $1.5M | Buy |
20,837
+15,609
| +299% | +$1.92M | ﹤0.01% | 1826 |
|
|
2019
Q3 | $733K | Buy |
5,228
+1,277
| +32% | +$214K | ﹤0.01% | 2014 |
|
|
2019
Q2 | $723K | Sell |
3,951
-2,156
| -35% | -$368K | ﹤0.01% | 1848 |
|
|
2019
Q1 | $971K | Sell |
6,107
-7,469
| -55% | -$1.08M | ﹤0.01% | 1711 |
|
|
2018
Q4 | $1.3M | Buy |
13,576
+4,320
| +47% | +$494K | ﹤0.01% | 1496 |
|
|
2018
Q3 | $1.31M | Buy |
9,256
+6,885
| +290% | +$1.06M | ﹤0.01% | 1649 |
|
|
2018
Q2 | $371K | Sell |
2,371
-7,327
| -76% | -$1.15M | ﹤0.01% | 2137 |
|
|
2018
Q1 | $1.56M | Buy |
9,698
+1,804
| +23% | +$306K | ﹤0.01% | 1491 |
|
|
2017
Q4 | $1.3M | Buy |
7,894
+972
| +14% | +$94.2K | ﹤0.01% | 1781 |
|
|
2017
Q3 | $431K | Buy |
6,922
+2,626
| +61% | +$206K | ﹤0.01% | 2064 |
|
|
2017
Q2 | $342K | Buy |
4,296
+3,674
| +591% | +$266K | ﹤0.01% | 2124 |
|
|
2017
Q1 | $44.2K | Sell |
622
-1,582
| -72% | -$92.7K | ﹤0.01% | 2783 |
|
|
2016
Q4 | $113K | Sell |
2,204
-165
| -7% | -$7.78K | ﹤0.01% | 2477 |
|
|
2016
Q3 | $109K | Buy |
2,369
+1,335
| +129% | +$54.3K | ﹤0.01% | 2058 |
|
|
2016
Q2 | $31.2K | Buy |
+1,034
| New | +$34.5K | ﹤0.01% | 2441 |
|
|
2016
Q1 | – | Sell |
-3,340
| Closed | -$195K | – | 3013 |
|
|
2015
Q4 | $195K | Buy |
3,340
+400
| +14% | +$19.8K | ﹤0.01% | 1947 |
|
|
2015
Q3 | $124K | Buy |
2,940
+1,793
| +156% | +$110K | ﹤0.01% | 2248 |
|
|
2015
Q2 | $83.7K | Buy |
1,147
+1,016
| +776% | +$65.3K | ﹤0.01% | 2180 |
|
|
2015
Q1 | $6.58K | Buy |
+131
| New | +$5.63K | ﹤0.01% | 2993 |
|
Other funds holding SAGE
IA
HNB
BNP Paribas Financial Markets's SAGE Position: Q3 2025 in Review
BNP Paribas Financial Markets sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 6,061 shares — an estimated $55.3K sold.
BNP Paribas Financial Markets first reported a position in SAGE in Q1 2015 and held it in 41 quarters. The position peaked at $7.28M in Q4 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- BNP Paribas Financial Markets reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- BNP Paribas Financial Markets sold 6,061 Sage Therapeutics shares in Q3 2025, an estimated $55.3K.
- BNP Paribas Financial Markets first reported a position in Sage Therapeutics in Q1 2015 and held it in 41 quarters.
- BNP Paribas Financial Markets's Sage Therapeutics position peaked at $7.28M in Q4 2023.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2025, filed 13 Nov 2025.